Physician profile
Anna Scott
NPI 1942852157
$15,581.40
in general payments reported to CMS, 2019-2025
32 companies · $4,491 in 2025
The $4,491 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $3,293 · 2023: $4,162 · 2024: $3,328 · 2025: $4,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,714.35 |
| Education | $266.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,784.56 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,392.96 | 2021-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $1,298.37 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $920.15 | 2022-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $899.98 | 2022-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $810.87 | 2021-2025 | |
| Dermavant Sciences, INC. | $809.76 | 2022-2024 | Vtama |
| Lilly USA, LLC | $802.71 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $775.60 | 2022-2025 | |
| Incyte Corporation | $771.75 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $666.64 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $559.84 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $526.67 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $445.69 | 2022-2025 | Sotyktu |
| Amgen INC. | $415.37 | 2023-2025 | Otezla, Otezla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $398.82 | 2022-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $381.70 | 2021-2025 | Jublia, Siliq, Cabtreo |
| Organon LLC | $231.58 | 2023-2025 | Vtama, Nexplanon, Hadlima |
| Epi Health, LLC | $177.47 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $135.79 | 2022-2025 | |
| Verrica Pharmaceuticals INC. | $63.40 | 2023-2025 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.96 | 2023-2025 | Spevigo |
| Botanix Sb INC | $40.49 | 2025 | Sofdra |
| Mylan Institutional INC. | $39.61 | 2023 | Hulio |
| Smith+Nephew, INC. | $33.52 | 2022 | |
| Kerecis Limited | $28.73 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Biocon Biologics INC | $24.43 | 2025 | Yesintek |
| Allergan, INC. | $22.02 | 2022 | |
| Journey Medical Corporation | $18.49 | 2022 | |
| Kyowa Kirin, INC. | $16.31 | 2022 | |
| Access Pro Medical, LLC | $14.24 | 2022 | |
| Almirall LLC | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.